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Background: Chronic eosinophilic inflammation may promote bronchial hyperresponsiveness
(BHR), which involves reversible reduction of airflow and airway remodelling such as a thick-
ening of the reticular basement membrane (RBM) and hypertrophy and hyperplasia of airway
smooth muscle (ASM). BHR to histamine (Hist) and acetylcholine (ACh) cannot differentiate
airway inflammation and remodelling.
Objective: To examine the correlations between eosinophilic inflammation or airway remodel-
ling and BHR to Hist or ACh in adults with severe asthma.
Methods: We examined eosinophils in the sputum of 50 adult patients with severe asthma
before inhaled corticosteroid (ICS) treatment. Airway responses to ACh and Hist were
measured on separate days after the first hospital visit and before bronchofiberscopy. Bron-
chial specimens were obtained by bronchofibrescopy for evaluation of RBM and ASM thickening
after systemic corticosteroid treatment.
Results: Eosinophil scores in the sputum before ICS treatment were correlated with BHR to ACh
but not to Hist. Asthma duration was inversely correlated with % forced expiratory volume in 1
s, %V50, %V25, BHR to Hist, and ASM thickness, but not BHR to ACh or RBM. A multivariate
logistic regression model showed that Long duration of asthma affected ASM thickness moreM, airway smooth muscle; BHR, bronchial hyperresponsiveness; FEV1, forced expiratory volume in 1 s;
mine; ICS, inhaled corticosteroid; MCh, methacholine; NO, nitric oxide; PC, provocative concentra-
ne; SCS, systemic corticosteroids; V50, maximum expiratory flow rate at 50% of forced vital capacity;
pport.
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1272 N. Tsurikisawa et al.than it affected %V50. ASM thickness was inversely correlated with BHR to Hist but not to ACh.
Conclusion: In adult patients with severe asthma, BHR to ACh is related to the degree of eosin-
ophilic airway inflammation, whereas BHR to Hist indicates airway remodeling, particularly
ASM hypertrophy.
ª 2010 Elsevier Ltd. All rights reserved.Introduction
Asthma is a chronic disease of the lower airways charac-
terized by airway inflammation, reversible airflow limita-
tion, and bronchial hyperresponsiveness (BHR). Chronic
eosinophilic inflammation in the lower airways may
promote airway remodelling, including epithelial desqua-
mation or loss of tight junctions,1e3 metaplasia of goblet
cells in the epithelium,4e6 thickening of the reticular
basement membrane (RBM),5,7e11 hypertrophy and hyper-
plasia of airway smooth muscle (ASM),5,8,9,12 fibrosis in the
sub-epithelium and lamina propria,5,7,8,13,14 an increase in
mucous glands,4,9 and increased angiogenesis.11,15,16
Airway remodelling is also influenced by the duration and
severity of asthma17e19 and by levels of serum IgE.20
Measures of asthmatic function, including BHR,21e23
small airway impairment24 measured as forced expiratory
volume in 1 s (FEV1), and maximum expiratory flow rate at
50% of forced vital capacity (V50), as well as markers of
airway inflammation such as eosinophils in sputum25 and
exhaled nitric oxide (NO),26,27 indicate the control of
asthma symptoms. BHR and airflow limitations interact and
are important risk factors for the development of asthma.
BHR to histamine (Hist), methacholine (MCh), acetyl-
choline (ACh), adenosine, mannitol, and exercise is widely
used to diagnose asthma.24,27 MCh and ACh cause bron-
choconstriction via muscarinic 3 (M3) receptors, whereas
Hist causes it directly via H1 receptors on bronchial smooth
muscle cells. However, the pharmacological and physical
differences in the types of bronchoconstriction induced by
these stimuli in humans are unclear.
Airway remodelling has been linked to BHR, to the
development of fixed airflow limitation, and to a long-term
decline in lung function in adult asthmatics.16,28,29 Airway
remodelling relates to the interaction of BHR to MCh and
RBM thickness,10,11 ASM hyperplasia,30 and the production
of tenascins13,31 and collagen types III and V in the sub-
epithelial layer.13 Lung function, as measured by changes in
predicted forced expiratory volume in 1 s (FEV1) or as FEV1/
forced vital capacity, is also correlated with changes in
ASM,12 RBM10,11 and the content of tenascins13 and colla-
gens III and V in the subepithelial layer.13 The interactions
of lung function, as measured by %FEV1 (% of predicted), %
V50, or %V25, with the abundance of airway inflammatory
cells (especially eosinophils), with BHR to Hist or ACh, and
with asthma duration are unclear. The relationships of
asthma duration with structural changes, BHR, inflamma-
tion, or airway remodelling are also unclear.
Here, we performed bronchial biopsies to measure
airway remodelling as RBM and ASM thickness, collected
epithelial eosinophils in sputum, and measured lung func-
tion by using BHR to Hist or ACh, %FEV1, %V50, and %V25. We
then examined the relationship between these factors andasthma duration, with the aim of developing measures to
improve asthma management.
Methods
Patients
We enrolled 50 men and women with severe asthma, each
of whom who had been admitted to the Clinical Research
Centre for Allergy and Rheumatology at the National
Hospital Organization, Sagamihara, with an asthma attack
between 2002 and 2007. All patients were diagnosed
according to the criteria of the American Thoracic
Society,32 and severity was assessed according the current
Global Initiative for Asthma (GINA) guidelines.24 Fifteen
control patients without asthma had suspected or actual
lung cancer. The study was approved by the hospital ethics
committee in accordance with the Helsinki Declaration,
and informed consent was obtained from each patient. The
exclusion criteria included pulmonary disease other than
asthma.
Study design
We measured eosinophil levels in sputum samples from
asthmatics by the Hansel classification system,33 and we
counted eosinophils in whole blood at the first hospital
visit, before inhaled corticosteroid (ICS) treatment. Eosin-
ophil levels in sputum were scored as 0 (none), 1 (few; 1 in
1 sight), 2 (slight; small numbers in 1 sight), 3 (mild;
moderate numbers in 1 sight), 4 (moderate; many in 1
sight), or 5 (severe; many in all sights), with scores of 0 and
1 consistent throughout the entire smear and scores of 2 to
5 verified under high power (400). By an intracutaneous
skin testing method described by Solley et al.,34 a 0.05-mL
solution of each of six allergensdhouse dust mite, cat, dog,
Alternaria tenuis, Aspergillus fumigatus, and rag-
weeddwas injected intradermally, and the result was
judged 15 min after injection. Histamine (0.4 mg) was used
as a positive control, and skin reactions were judged posi-
tive if they were larger than the histamine reaction. Atopy
was defined as a positive intracutaneous skin reaction to at
least one antigen. The provocation tests with ACh or
histamine (Hist) were performed (see below) on separate
days within 1 month after the first hospital visit and within
2 weeks before bronchofiberscopy. All patients were
treated with anti-asthma drugs such as short-acting b2
agonists or sustained-release theophylline excluding ICS
within first 1 month. All patients needed treatment with
systemic corticosteroid (SCS) because they each had had an
attack of asthma on admission. Before the bronchoscopy,
all patients were treated with SCS (12 mg betamethasone)
Table 1 Patient characteristics.
Patients without asthma
(control)a NZ 15
Patients with asthma NZ 50
Mean (SEM) age (years) 52.9 (3.0) 54.5 (2.0)
Sex (M:F) 8:7 26:24
Smoking history: never/ex/current 8/4/3 42/6/2
Mean (range) age at onset of asthma (years) 38.5 (0.3e70)
Mean (range) duration of asthma (years) 16.0 (0.4e54)
Type: atopy to non-atopy ratio 21:29
Severity: Step 1/2/3/4 0/0/0/50
At first hospital visit
Mean (SEM) Eosinophil count (% of white blood cells) 11.2 (1.2)
Score of eosinophils in sputumb (0/1/2/3/4/5) 8/6/6/19/6/3
Mean (SEM) VC (% predicted) 99.8 (2.9)
Mean (SEM) FEV1 (% predicted) 78.9 (3.2)
Mean (SEM) V50 (% predicted) 50.3 (3.8)
Mean PC20-Ach (range) (mg/mL) 4508.2 (110e20,000)
Mean PC20-Hist (range) (mg/mL) 820.4 (26e10,000)
Treatment at bronchial biopsy
ICS mean (SEM) (mg FP equivalent) 968.0 (57.2)
SCS N (%) 5 (10.0)
Long-acting b2 agonists N (%) 36 (72.0)
Leukotriene receptor antagonist N (%) 31 (62.0)
Sustained-release theophylline N (%) 42 (84.0)
At bronchial biopsy
Mean (SEM) FEV1 (% predicted) 84.4 (2.8)
Mean (SEM) V50 (% predicted) 57.0 (3.3)
Mean PC20-Ach (range) (mg/mL) 7998.3 (135e20,000)
Mean PC20-Hist (range) (mg/mL) 1111.7 (68e10,000)
a Disease was actual or suspected lung cancer; NZ 10; interstitial pneumoniae NZ 5.
b According to the Hansel classification.33
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addition to other anti-asthma drugs such as ICS, long-acting
b2 agonists, leukotriene receptor antagonists, or sustained-
release theophylline (Table 1). We then took bronchial
specimens by bronchofiberscopy. All patients continued
treatment with anti-asthma drugs. RBM and ASM thick-
nesses were measured in sections of bronchial specimens
stained with hematoxylin and eosin (H&E).Measurement of bronchial hyperresponsiveness to
ACh and Hist
Inhalation testing was performed by modifying the method
according to ATS guidelines.35 All anti-asthma medications
were withheld for at least 12 h before the provocation test.
We prepared ACh chloride (Ovisot, Daiichi PharmaceuticalTable 2 Differences in thickness of RBM and ASM and in numbe
Patients without ast
RBM mean (SEM) (mm) 4.0 (0.7)
ASM mean (SEM) (mm) 4.4 (0.5)
Eosinophils mean (SEM) (cells/mm2) 0.06 (0.04)
Differences between groups were evaluated by ManneWhitney U-testCo. Ltd, Tokyo, Japan) at 0.157, 0.316, 0.625, 1.25, 2.5, 5,
10, and 20 mg/mL, and Hist dihydrochloride (Sigma, St
Louis, MO, USA) at 0.078, 0.157, 0.316, 0.625, 1.25, 2.5, 5,
and 10 mg/mL by dilution in buffered saline solution (pH
7.4). FEV1 was measured with a spirometer (Auto Spiro AS-
303, Minato Medical Science Co. Ltd, Osaka, Japan) after
each inhalation. The subjects inhaled ACh aerosol from
a nebulizer (DeVilbiss 646, DeVilbiss Co., Somerset, PA,
USA) by tidal breathing for 2 min. The operating airflow of
this device was 5 L/min. Isotonic saline was inhaled first as
a control. Patients with FEV1< 1.00 L or showing a decrease
of >10% with saline alone were not tested further.
Increasing concentrations of ACh or Hist were then inhaled
until FEV1 fell by >20% of its post-saline value or until the
maximum ACh or Hist concentration was reached. The
percentage fall in the FEV1 from the post-saline solution
value was plotted against the log concentration of inhaledrs of eosinophils in bronchial specimens.
hma (control) Patients with asthma P-value
8.9 (0.6) 0.01
9.2 (0.4) 0.01
0.61 (0.12) 0.0583
.
Table 3 Correlations between duration of asthma and
lung function, BHR to Ach or Hist, and RBM or ASM thickness.
rs P
%FEV1 0.365 0.01*
%V50 0.526 <0.01**
%V25 0.349 0.02*
PC20-Ach (mg/mL) 0.275 0.054
PC20-Hist (mg/mL) 0.433 <0.01**
RBM (mm) 0.273 0.055
ASM (mm) 0.484 <0.01**
rs: Correlations were analyzed by Spearman’s rank correlation
test. **P< 0.01, *P< 0.05.
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provocative concentration (PC) of the agonist causing
a decrease in FEV1 of >20% (PC20). At the end of the test,
any fall in the FEV1 was reversed by the inhalation of sal-
butamol (0.5 mL of 5 mg/mL). Subjects with a PC20-ACh of
<20 mg/mL or a PC20-Hist of <10 mg/mL were defined as
having a positive BHR.
Bronchoscopy and bronchial biopsies
Bronchoscopy was performed according to international
guidelines.36 After pre-medication with 4% lidocaine from
anebulizer, each patientwas anesthetized intravenouslywith
3 mg midazolam hydrochloride. The bronchoscope (Olympus
BF-1T240, Olympus Optical Co., Tokyo, Japan) was inserted
through the mouth and pharynx, and the trachea and bronchi
were anesthetized with 4% lidocaine in 3 L/min of oxygen via
nasal cannulae. Two or three bronchial specimens were taken
from the right upper- and lower-lobe bronchi.
Measurement of basement membrane and airway
smooth muscle thickness
Biopsy specimens were fixed in 10% formaldehyde,
embedded in paraffin, cut at 3 mm, and stained with H&E.
RBM thickness was assessed in five sections from two
different biopsy specimens from the base of the bronchial
epithelium to the outer limit of the reticular layer.10 The
diameter of ASM cells across the nucleus was measured in at
least five cells in randomly selected fields of two different
biopsy specimens.5 We used image analysis software (Image
Pro Plus 5.0, Media Cybernetics, MD, USA) to evaluate RBM
and ASM thickness.Table 4 Logistic regression model of baseline factors predictiv
Variable Exponent
%FEV1 0.959
%V50 1.097
%V25 0.975
PC20-Ach (mg/mL) 0.497
PC20-Hist (mg/mL) 0.826
RBM (mm) 1.291
ASM (mm) 0.509
** P< 0.01, * P< 0.05 by logistic regression.Statistical analysis
All values are expressed as means SD (range) unless
otherwise specified. Statistical comparisons between
groups were performed with the ManneWhitney U-test or
the unpaired Student’s t-test. Correlation coefficients were
obtained by Spearman’s rank correlation test. A multiple
logistic regression analysis was used to calculate risk factor
coefficients. Values of P< 0.05 were considered statisti-
cally significant. Statistical analysis was performed with
StatView v. 5.0 software (SAS Institute; Cary, NC, USA).
Results
Clinical findings
The mean age of the patients with asthma was 54.5 2.0
years (range 27e77 years); the mean age at onset of asthma
was 38.5 2.6 years (0.3e70 years); and the mean duration
of asthmawas16.0 1.8 years (0.4e54 years) (Table1).More
patients had non-atopic asthma. All patients were classified
into Step 4 in the GINA guidelines at bronchial biopsy. FEV1
improved from 78.9% 3.2% at the first hospital visit to
84.4% 2.8% at biopsy (P< 0.01), and %V50 improved from
50.3% 3.8% to 57.0% 3.3% at biopsy (P< 0.01), but
impairment of the small airways remained. PC20-ACh and
PC20-Hist improved after treatment with systemic steroids
from 4508 and 820 mg/mL, respectively, at the first hospital
visit to 7998 and 1112 mg/mL at biopsy (P< 0.01). However,
PC20 at biopsy had wide ranges of 135 to 20,000 mg/mL (PC20-
ACh) and 68 to 10,000 mg/mL (PC20-Hist) after treatment
with SCS. Non-asthma patients had actual or suspected Stage
I lung cancer. None of these patients had abnormal bronchial
mucous findings. RBM and ASM were thicker in asthmatics
than in controls (Table 2). We found very few eosinophils in
bronchial specimens, because we performed bronchial
biopsy after treatmentwith SCS; thenumber of eosinophils in
patients with asthma was not significantly different from
that in control patients (P> 0.05; Table 2).
Asthma duration is correlated with lung function,
BHR, and bronchial pathology
Asthma duration was correlated with %FEV1 (PZ 0.01), %V50
(P< 0.01), %V25 (PZ 0.02), PC20-Hist (P< 0.01), and ASM
thickness (P< 0.01), but not with PC20-ACh or RBM thickness
(Table 3) or airway eosinophilic inflammation (PZ 0.58,e of the duration of asthma >15 years vs. <15 years.
95% CI P-value
0.902e1.021 0.19
1.013e1.188 0.03*
0.931e1.021 0.28
0.058e4.245 0.52
0.155e4.393 0.82
0.917e1.817 0.14
0.305e0.850 0.0098**
Table 5 Correlations between ASM thickness and BHR to
Ach or Hist and lung function.
rs P
%FEV1 0.147 0.32
%V50 0.201 0.17
%V25 0.264 0.07
PC20-Ach (mg/mL) 0.232 0.11
PC20-Hist (mg/mL) 0.385 P< 0.01**
rs: Correlations were analyzed by Spearman’s rank correlation
test. ** P< 0.01.
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to determine factors predictive of asthma duration longer
than 15 years or less than 15 years. Long-term duration
influenced ASM thickness most (P< 0.01) and %V50 second-
arily (P< 0.05; Table 4). ASM thickness was correlated with
PC20-Hist (rsZ0.385, P< 0.01; Table 5). Thus, long-term
asthma promoted airway remodelling, seen as increased
ASM thickness, as a reflection mainly of PC20-Hist.
Correlation between eosinophil levels in sputum
and BHR to ACh or Hist
Eosinophil levels in thesputumat thefirsthospital visit, before
ICS, were correlated with PC20-ACh (P< 0.01, rsZ0.57),
but not with PC20-Hist (PZ 0.11, rsZ0.24; Fig. 1).
However, the number of eosinophils in the airways at biopsy,
after patients received SCS therapy, was not correlated with
BHR to ACh (PZ 0.60, rsZ 0.08) or Hist (PZ 0.14, rsZ 0.21).
Pathological findings in the bronchial biopsy
RBM and ASM were thinner in controls (Fig. 2A) than in
asthmatics (Fig. 2B, C; P< 0.01; Table 2). ASM thickness
was correlated with BHR to Hist (Table 5). Despite similar
asthma duration and BHR to ACh, patients B and C showed
different BHRs to Hist (B, 10,000 mg/mL; C, 657 mg/mL).
There were few eosinophils in the bronchium in patients B
and C, and there were eosinophils in the airways in asth-
matic patients as few as in control subjects (PZ 0.058).
ASM thickness in patients with high PC20-ACh and low PC20-
Hist did not differ from that in patients with low PC20-ACh
and low PC20-Hist (data not shown).A
Figure 1 Correlation between eosinophils in sputum (x-axis) and
were classified as 0 (none) to 5 (severe). (A) PC20-ACh: P< 0.01, rRelationship between BHR to ACh and BHR to Hist
PC20-ACh was correlated with PC20-Hist (Fig. 3; P< 0.01,
rsZ 0.52), but PC20-Hist was lower than PC20-ACh in each
patient; that is, most patients were more sensitive to Hist
than to ACh, and BHR to ACh and Hist showed heterogeneity.Discussion
Long-term asthma was correlated with ASM thickness and
lung function measured as %V50. ASM thickness was corre-
lated with BHR to Hist. Eosinophil levels in sputum were
correlated with BHR to ACh but not BHR to Hist. Thus, in
adult asthmatics, eosinophilic inflammation is reflected by
BHR to ACh, whereas airway remodelling seen as ASM
hypertrophy relates better to BHR to Hist. To verify our
conclusions on the basis of the semi-quantitative data
generated by Hansel classification, we compared the
Hansel scores with the percentage of eosinophils in sputum
in 36 new patients with general asthma. A significant linear
correlation (P< 0.01, rsZ 0.94) confirmed that our results
by Hansel score reflected airway eosinophilic inflammation.
BHR and reversible airflow limitations are correlated
with airway inflammation: significant correlations occur
between exhaled NO and PC20-MCh, sputum eosinophils and
FEV1, sputum eosinophils and PC20-MCh,
25 and epithelial
eosinophils and PC20-MCh.
10 Exhaled NO is correlated with
PC20-Hist in patients with mild asthma who have not been
treated with ICS, but not in patients treated with ICS.26
Because of the influence of ICS treatment, we measured
BHR to ACh and Hist before ICS treatment. BHR to ACh was
correlated with BHR to Hist (rsZ 0.52, P< 0.01), but
patients were more sensitive to Hist than to ACh, indicating
heterogeneity between BHR to ACh and to Hist.
Airway structural changes are stimulated by inflamma-
tory cells, including eosinophils,8,5,30 lymphocytes,19,37
mast cells,13,28 and neutrophils.19 Our results indicated
that sputum eosinophil scores before ICS treatment were
correlated with BHR to ACh but not to Hist (Fig. 1).
However, we found few eosinophils and no neutrophils in
the bronchial specimens, because bronchial biopsy was
performed after steroid treatment.
The mechanism of bronchial contraction stimulated by
Hist, MCh, and ACh is complex. Hist is a typical mediator ofB
BHR to (A) ACh and (B) Hist. The scores of eosinophils in sputum
sZ0.57. (B) PC20-Hist: PZ 0.11, rsZ0.24.
Figure 2 H&E staining (100). (A) Control subject without asthma. (B) 66-year-old man with asthma for 8 years; PC20-
AChZ 20,000 mg/mL, PC20-HistZ 10,000 mg/mL (low BHR to Hist). (C) 65-year-old woman with asthma for 6 years; PC20-
AChZ 13,990 mg/mL, PC20-HistZ 657 mg/mL (high BHR to Hist). RBMZ reticular basement membrane; ASMZ airway smooth muscle.
1276 N. Tsurikisawa et al.the allergic response, as well as a cholinergic agonist that
directly activates H1 receptors on bronchial smooth muscle
cells and stimulates bronchial contraction via the vagal
reflex.38 Release of ACh from postganglionic para-
sympathetic fibres stimulates smooth muscle contraction
by binding to M3 receptors on smooth muscle cells. Hist
produces a greater contractile response than MCh,39 but
the two have similar potencies,40 with similar airway
sensitivities and specificities and positive predictive values
for asthma diagnosis.27 Our patients with long-term asthma
had more sensitive BHR to Hist than to ACh. BHR to Hist in
these patients did not improve more than that in patients
with short-term asthma. This confirms that long-term
asthma induces airway remodelling.Figure 3 Correlation between BHR to ACh and BHR to Hist
(same patient on different days within 1 month after bronchial
biopsy). Airway responses to ACh and Hist were measured as
the concentration of ACh or Hist that led to a >20% reduction
in FEV1. Log PC20-ACh was significantly correlated with log
PC20-Hist (P< 0.01, rsZ 0.52).Long-term asthma increases airway remodelling
processes such as ASM hyperplasia,17 and older patients who
die of asthma have more muscle in the airway wall than
younger patients who die of asthma.18 Long-term asthma
(>10 years) produces greater ASM hypertrophy than impair-
ment of BHR or obstruction of small airways. BHR is corre-
lated with RBM thickness,10,11 ASM hyperplasia,30
subepithelial fibrosis,13 or airway wall thickening in
patientswith reducedBHR toMCh.41 BHR toMCh is correlated
with eosinophils in sputum and NO in patients with short-
term asthma (<16 years), but BHR to MCh is correlated
with lung function in long-term patients (>16 years).42 These
results suggest that long-term asthma does not affect airway
inflammation. Our results show that eosinophilic inflamma-
tion in airways was correlated with BHR to ACh but not to
Hist; that asthma duration was related to ASM hypertrophy
(Table 4); and that ASM hypertrophy reflected BHR to Hist.
We conclude that BHR to ACh reflects eosinophilic inflam-
mation, whereas BHR to Hist reflects airway remodelling.We
hypothesize that ASM may have higher numbers of H1
receptors, but notM3 receptors, allowing ASMhypertrophy to
reflect both airway remodelling and BHR to Hist, althoughwe
cannot confirm this. Testing of this hypothesis may elucidate
the mechanism of airway remodelling in the future.
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